Total Payments
$15,320
2024 Payments
$1,161
Companies
36
Transactions
286
Medicare Patients
15,004
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$8,287 (54.1%)
Other$7,021 (45.8%)
Education$12.45 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,287 | 282 | 54.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,021 | 3 | 45.8% |
| Education | $12.45 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $7,045 | 5 | $0 (2021) |
| Abbott Laboratories | $1,534 | 18 | $0 (2023) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $848.72 | 41 | $0 (2024) |
| Medtronic, Inc. | $711.33 | 10 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $607.12 | 42 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $504.21 | 21 | $0 (2024) |
| PFIZER INC. | $434.16 | 26 | $0 (2024) |
| Edwards Lifesciences Corporation | $389.55 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $362.23 | 22 | $0 (2023) |
| AtriCure, Inc. | $350.18 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,161 | 38 | Edwards Lifesciences Corporation ($198.76) |
| 2023 | $1,642 | 52 | Abbott Laboratories ($463.01) |
| 2022 | $1,818 | 43 | Medtronic, Inc. ($389.50) |
| 2021 | $8,001 | 40 | Allergan, Inc. ($7,021) |
| 2020 | $543.59 | 26 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($139.26) |
| 2019 | $935.21 | 48 | Abbott Laboratories ($168.87) |
| 2018 | $742.80 | 20 | Abbott Laboratories ($222.75) |
| 2017 | $476.77 | 19 | Abbott Laboratories ($259.01) |
All Payment Transactions
286 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $19.60 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/10/2024 | Edwards Lifesciences Corporation | SAPIEN 3 Ultra RESILIA (Device) | Food and Beverage | In-kind items and services | $198.76 | General |
| Category: Transcatheter Heart Valves | ||||||
| 11/14/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | Food and Beverage | Cash or cash equivalent | $24.00 | General |
| Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 11/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: DIABETES | ||||||
| 10/24/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/17/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/10/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $20.22 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/01/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $29.90 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/30/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Obesity | ||||||
| 09/19/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.51 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/12/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.86 | General |
| Category: Cardiovascular | ||||||
| 09/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/29/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/13/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $28.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/08/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/25/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/16/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Not Applicable | ||||||
| 05/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/09/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 04/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $7.12 | General |
| Category: Cardiovascular | ||||||
| 04/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $126.00 | General |
| 04/14/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Diabetes | ||||||
| 04/11/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 3,369 | 4,041 | $1.1M | $351,170 |
| 2022 | 30 | 4,018 | 4,809 | $1.0M | $333,379 |
| 2021 | 34 | 3,906 | 4,679 | $1.0M | $327,076 |
| 2020 | 34 | 3,711 | 4,677 | $735,958 | $241,955 |
Total Patients
15,004
Total Services
18,206
Medicare Billing
$1.3M
Procedure Codes
131
All Medicare Procedures & Services
131 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 360 | 365 | $164,120 | $55,897 | 34.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 584 | 775 | $155,000 | $54,457 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 333 | 440 | $127,600 | $43,596 | 34.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 196 | 196 | $72,520 | $26,020 | 35.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 69 | 69 | $71,415 | $25,785 | 36.1% |
| 93241 | Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 95 | 98 | $73,500 | $22,178 | 30.2% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 104 | 105 | $56,700 | $18,922 | 33.4% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 71 | 71 | $44,730 | $14,817 | 33.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 68 | 68 | $30,520 | $10,932 | 35.8% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 62 | 236 | $17,700 | $10,464 | 59.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 621 | 669 | $56,515 | $7,829 | 13.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 150 | 161 | $20,930 | $7,547 | 36.1% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 69 | 69 | $23,975 | $7,143 | 29.8% |
| 93303 | Ultrasound of heart for congenital defect | Office | 2023 | 31 | 31 | $15,965 | $5,892 | 36.9% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 12 | 13 | $16,445 | $5,772 | 35.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 52 | 52 | $13,000 | $4,896 | 37.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 33 | 33 | $12,375 | $4,228 | 34.2% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 75 | 75 | $12,000 | $3,938 | 32.8% |
| 93454 | Insertion of tube in coronary artery for diagnosis with review by radiologist | Facility | 2023 | 21 | 22 | $11,220 | $3,918 | 34.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 62 | 151 | $9,815 | $3,541 | 36.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 40 | 42 | $6,090 | $2,181 | 35.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 19 | $4,940 | $1,831 | 37.1% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 13 | 14 | $5,950 | $1,820 | 30.6% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 35 | 35 | $4,500 | $1,497 | 33.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 19 | 19 | $3,990 | $1,416 | 35.5% |
About Dr. Robert Marshall, M.D
Dr. Robert Marshall, M.D is a Cardiovascular Disease healthcare provider based in Chevy Chase, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053365189.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Marshall, M.D has received a total of $15,320 in payments from pharmaceutical and medical device companies, with $1,161 received in 2024. These payments were reported across 286 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($8,287).
As a Medicare-enrolled provider, Marshall has provided services to 15,004 Medicare beneficiaries, totaling 18,206 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 131 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Chevy Chase, MD
- Active Since 05/22/2006
- Last Updated 12/29/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1053365189
Products in Payments
- LifeVest (Device) $848.72
- ELIQUIS (Drug) $656.84
- Confirm Rx (Device) $498.88
- ENTRESTO (Drug) $485.20
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $463.01
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) $337.12
- Repatha (Biological) $266.24
- BRILINTA (Drug) $257.43
- NEXLETOL (Drug) $234.43
- SAPIEN 3 Ultra RESILIA (Device) $198.76
- ONYX FRONTIER (Device) $176.09
- MICRA (Device) $175.77
- Ozempic (Drug) $172.57
- COBALT DR MRI SURESCAN (Device) $171.17
- General - Therapies (Device) $170.14
- XARELTO (Drug) $168.00
- COREVALVE EVOLUT R (Device) $157.31
- Barostim Neo System (Device) $149.17
- Resolute (Device) $147.54
- Quadra Assura CRT Defibrillator (Device) $143.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Chevy Chase
Dr. Richard Rubin, M.d, M.D
Cardiovascular Disease — Payments: $65,902
Cardiovascular Disease $65,902
Dr. Ankit Shah, M.d., M.p.h, M.D., M.P.H
Cardiovascular Disease — Payments: $30,739
Cardiovascular Disease $30,739
Dr. Jack Flyer, M.d, M.D
Cardiovascular Disease — Payments: $19,663
Cardiovascular Disease $19,663
Barry Talesnick, M.d, M.D
Cardiovascular Disease — Payments: $14,217
Cardiovascular Disease $14,217
Joseph Vassallo, M.d, M.D
Cardiovascular Disease — Payments: $14,106
Cardiovascular Disease $14,106
Sean Dwyer, M.d, M.D
Cardiovascular Disease — Payments: $9,280
Cardiovascular Disease $9,280